Abstract
Despite the chemical similarities between myo-inositol and D-chiro-inositol and their synergistic effects on insulin sensitivity, they serve different functions. Insulin resistance is one of the etiological factors in the development of polycystic ovary syndrome (PCOS), diabetes mellitus, metabolic syndrome, infertility, menstrual irregularities and ovulation disorders, pregnancy complications, in particular, gestational diabetes. Myo-inositol plays an important role in the insulin transfer and hormone synthesis in the ovaries, in oocyte maturation, fertilization, implantation and post-implantation development.Many studies confirm the positive effect of inositol isomers on metabolic, hormonal and reproductive disorders, both in the form of monotherapy and in combination with other drugs to enhance the therapeutic effect and bioavailability. Myo-inositol has a favorable safety profile. Studies have shown that in patients with PCOS myo-inositol improves ovarian function and fertility, reduces the manifestations of hyperandrogenism, insulin resistance and normalizes weight.Myo-inositol and D-chiro-inositol have different mechanisms of action on insulin sensitivity and have different functions. The balance of the two isomers ensures the normal secretion of hormones and ovarian functioning, but it is currently unknown what the optimal ratio of these two isomers due to the small number of high quality studies and the difficulty of studying their isolated action.There are currently different combinations of myo- and D-chiro-inisotol, but they also have not been supported by enough high quality studies. When prescribing various isomers of inositol, it should be remembered that doses above 4000 mg are the most studied in patients with PCOS, but D-chiro-inositol concentration above 1200 mg/day has undesirable effects. Most studies indicate that D-chiro-inositol value is increased in PCOS, therefore oocytes are more sensitive to its overdose, and combination drugs require more study. Currently, there is no consensus in the literature on the advantage of combined supplements of myo- and D-chiro-inositol compared to monotherapy with myo-inositol. Today, myo-inositol monotherapy is more researched and safer.
Highlights
Many studies confirm the positive effect of inositol isomers on metabolic
The balance of the two isomers ensures the normal secretion of hormones
Most studies indicate that D-chiro-inositol value is increased in
Summary
При збільшенні дози DХІ до 2400 мг у пацієнток не тільки був відсутній ефект від терапії на чутливість тканин до інсуліну, а й спостерігалися погіршення якості ооцитів, ембріонів та зниження відповіді яєчників до ФСГ [13, 33]. Для подальших висновків про ефекти різних ізомерів інозитолу необхідні масштабні рандомізовані контрольовані подвійні сліпі дослідження, щоб визначити, чи можна використовувати для лікування різні ізомери інозитолу для зниження ризику ЦД або як доповнення до наявних методів терапії ЦД та інших станів порушення регуляції інсуліну. D., Corrado, F., Santamaria, A., et al “Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: A perspective, randomized, placebo-controlled study.”. V., Nestler, J.E., Kamenov, Z.A., et al “Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials.”Int J Endocrinol 2016 (2016): 1849162. DOI: disturbed inositol metabolism, and inhibited protein kinase C activity.”
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
